Updated Vitaxin Phase II data

MedImmune (MEDI) said updated data from a Phase II trial showed that stage IV metastatic melanoma patients given Vitaxin had a one-year survival rate of 53%, compared with 42% for Vitaxin plus dacarbazine (DTIC). ...